184.66
-3.36 (-1.79%)
| Penutupan Terdahulu | 188.02 |
| Buka | 187.69 |
| Jumlah Dagangan | 244,072 |
| Purata Dagangan (3B) | 651,259 |
| Modal Pasaran | 9,309,198,336 |
| Harga / Pendapatan (P/E Ke hadapan) | 344.83 |
| Harga / Jualan (P/S) | 16.31 |
| Harga / Buku (P/B) | 127.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Feb 2026 |
| Margin Keuntungan | -64.39% |
| Margin Operasi (TTM) | -45.67% |
| EPS Cair (TTM) | -5.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 397.02% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | -118.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.98 M |
| Pulangan Atas Aset (ROA TTM) | -26.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -282.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Axsome Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 76.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Macquarie Group Ltd | 30 Sep 2025 | 1,084,536 |
| Deep Track Capital, Lp | 30 Sep 2025 | 900,000 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 815,176 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 746,398 |
| Alethea Capital Management, Llc | 30 Sep 2025 | 670,883 |
| Orbimed Advisors Llc | 30 Sep 2025 | 531,800 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 260.00 (HC Wainwright & Co., 40.80%) | Beli |
| Median | 205.00 (11.02%) | |
| Rendah | 169.00 (Needham, -8.48%) | Beli |
| Purata | 213.67 (15.71%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 169.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 21 Jan 2026 | 219.00 (18.60%) | Beli | 189.10 |
| 04 Nov 2025 | 198.00 (7.22%) | Beli | 134.93 | |
| HC Wainwright & Co. | 20 Jan 2026 | 260.00 (40.80%) | Beli | 184.50 |
| 05 Jan 2026 | 200.00 (8.31%) | Beli | 171.49 | |
| Piper Sandler | 16 Jan 2026 | 223.00 (20.76%) | Beli | 177.27 |
| Wells Fargo | 13 Jan 2026 | 193.00 (4.52%) | Beli | 174.33 |
| 04 Nov 2025 | 157.00 (-14.98%) | Beli | 134.93 | |
| Morgan Stanley | 08 Jan 2026 | 204.00 (10.47%) | Pegang | 167.55 |
| 04 Nov 2025 | 196.00 (6.14%) | Beli | 134.93 | |
| UBS | 06 Jan 2026 | 248.00 (34.30%) | Beli | 171.88 |
| Needham | 31 Dec 2025 | 169.00 (-8.48%) | Beli | 182.64 |
| 04 Nov 2025 | 154.00 (-16.60%) | Beli | 134.93 | |
| Mizuho | 06 Nov 2025 | 202.00 (9.39%) | Beli | 139.41 |
| Guggenheim | 04 Nov 2025 | 205.00 (11.01%) | Beli | 134.93 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |